The Literature, Set In Order

The foundational characterization of ipamorelin was published in the European Journal of Endocrinology in 1998 by Raun and colleagues at Novo Nordisk ^[1]. The paper describes the pentapeptide as the first growth hormone secretagogue receptor agonist with growth-hormone-release selectivity comparable to growth hormone-releasing hormone itself.

In anesthetized rat, the median effective dose for growth hormone release after intravenous administration was 80 ± 42 nmol/kg, with a maximal response of 1545 ± 250 ng growth hormone per millilitre ^[1]. In conscious swine, the effective dose was lower — 2.3 ± 0.03 nmol/kg intravenous — with a maximal growth hormone response of 65 ± 0.2 ng/ml. The selectivity finding sits in the paper's central table: at doses two hundred times the growth-hormone median effective dose, neither adrenocorticotropic hormone nor cortisol rose significantly above control. Prolactin was likewise not perturbed ^[1].

This is the result the rest of the ipamorelin literature is built on. The selectivity argument has been replicated in subsequent in vitro and in vivo work ^[12] and is what differentiated ipamorelin from the earlier growth hormone-releasing peptides — GHRP-6, GHRP-2, hexarelin — that shared its receptor target but lifted adrenocorticotropic hormone and cortisol along with growth hormone. The pentapeptide structure (Aib-His-D-2-Nal-D-Phe-Lys-NH2), with two non-natural residues (alpha-aminoisobutyric acid and D-2-naphthylalanine) and a C-terminal amide, was deliberately engineered to retain ghrelin-receptor agonism while shedding the off-target activity that complicated earlier GHRPs ^[1].

Gobburu, Agerso, Jusko and Ynddal published a pharmacokinetic-pharmacodynamic modeling study in Pharmaceutical Research in 1999, working with healthy human male volunteers who received single intravenous bolus doses across a dose range ^[2]. The data are the closest the published literature comes to a human reference set for ipamorelin disposition.

The parameters from the model are: terminal elimination half-life ≈ 2 hours, plasma clearance 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg ^[2]. The pharmacokinetics were dose-proportional across the range tested. Growth hormone — the pharmacodynamic endpoint — peaked at approximately 0.67 hours (40 minutes) post-dose and declined exponentially toward baseline over the subsequent two to three hours. The authors derived a useful indirect-response model linking serum ipamorelin concentration to pituitary growth hormone release.

Two qualifications apply. First, this is a small healthy-volunteer study with a narrow demographic; the data do not extend to women, to chronic dosing, to subcutaneous or oral or intranasal routes, or to any patient population. Second, no subsequent human pharmacokinetic study of comparable rigor has been published. The Gobburu paper, twenty-six years on, remains the human reference ^[2].

A trio of rodent studies through the late 1990s and early 2000s situated ipamorelin in the growth-hormone / insulin-like-growth-factor-1 / bone-formation literature. Johansen and colleagues administered 0, 18, 90, and 450 micrograms per day subcutaneously, divided three times daily, to adult female Sprague-Dawley rats for 15 days ^[3]. Longitudinal bone growth rate increased dose-dependently from 42 micrometres per day in the vehicle group to 44, 50, and 52 micrometres per day across the three active doses (p < 0.0001).

Svensson and colleagues followed in 2000 with a 12-week chronic dosing study — 0.5 mg/kg/day delivered by continuous subcutaneous osmotic minipump in 13-week-old female Sprague-Dawley rats ^[4]. Total tibial and vertebral bone mineral content rose significantly versus vehicle, with some parameters comparable to recombinant growth hormone administered at 3.5 mg/kg/day. The same group then demonstrated, in a 2001 paper, that ipamorelin co-administered with a glucocorticoid in 8-month-old female rats restored periosteal bone formation rate roughly fourfold over glucocorticoid alone ^[5]. The mechanistic implication — that GHS-R1a agonism can partially offset glucocorticoid-induced suppression of bone anabolism — is consistent with the broader growth-hormone / insulin-like-growth-factor-1 axis literature, but it has not been tested in human bone-disease populations.

A separate research thread examined ipamorelin as a ghrelin mimetic in models of gastrointestinal dysmotility. Greenwood-Van Meerveld and colleagues, working with adult male Sprague-Dawley rats (225–275 g) in a model of postoperative ileus, administered intravenous doses of 0.014 and 0.14 micromol/kg ^[6].

At the higher dose, less than 25% of an orally administered radiolabel was retained in the stomach at 15 minutes — compared to 78 ± 5% retention in the vehicle group. Small-bowel transit, measured by the geometric centre of the radiolabel along the intestinal tract, was normalized to control values. In parallel in vitro work, 1 micromolar ipamorelin produced contractile responses in isolated intestinal tissue that were blocked by atropine, implicating cholinergic enteric pathways downstream of GHS-R1a activation ^[6]. This rodent result was the proximate motivation for the human Phase 2 trial that followed.

The single published Phase 2 efficacy trial of ipamorelin in any human population is Beck, Sweeney and McCarter's 2014 paper in the International Journal of Colorectal Disease, reporting the work of the Ipamorelin 201 Study Group ^[7]. The trial enrolled 114 adults undergoing bowel resection and randomized them to ipamorelin (0.03 mg/kg intravenous twice daily for up to 7 days or until discharge) or matching placebo. The primary endpoint was time to first tolerated solid meal.

Median time to first tolerated solid meal was 25.3 hours in the ipamorelin arm versus 32.6 hours in the placebo arm. The seven-hour numerical difference favoured ipamorelin but did not reach statistical significance: p = 0.15 ^[7]. The trial therefore missed its primary endpoint. Adverse-event rates were 87.5% on ipamorelin and 94.8% on placebo, with no specific safety signal flagged.

The trial's importance to the wider literature is not the efficacy result — which was null — but its existence. NCT00672074 is the only registered, completed, published Phase 2 trial of ipamorelin in any indication, in any patient population, of any duration. Helsinn discontinued clinical development of ipamorelin after the 2014 publication, and no successor Phase 3 trial has been registered or published in the eleven years since ^[7]. Every claim about ipamorelin's clinical activity in humans rests on this single negative trial plus the 1999 healthy-volunteer pharmacokinetic paper ^[2].

Two regulatory items belong on the broadside.

The first is the October 29, 2024 meeting of the United States Food and Drug Administration's Pharmacy Compounding Advisory Committee ^[13]. The committee was asked to vote on whether ipamorelin (free base and ipamorelin acetate) should be added to the 503A bulks list — the list of bulk drug substances permitted for use by compounding pharmacies under section 503A of the Federal Food, Drug, and Cosmetic Act. The committee voted against inclusion, citing concerns over identity and characterization data and inadequate safety information for chronic human exposure. The associated briefing document compiled chemistry, nonclinical toxicology, and clinical-data summaries and constitutes the most recent comprehensive regulatory review of ipamorelin in the United States.

A related procedural action preceded the meeting. Effective September 27, 2024, ipamorelin acetate was removed from Category 2 of the interim 503A bulks list following withdrawal of its nomination ^[14]. The combined effect — removal from Category 2 and a negative PCAC vote on inclusion in the final list — meaningfully constrains the lawful supply of compounded ipamorelin from United States pharmacies.

The second regulatory item is the World Anti-Doping Agency's classification. Ipamorelin appears on the WADA Prohibited List under category S2.2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times in and out of competition in all WADA-code sports ^[15]. Validated urinary detection methods based on liquid chromatography–high-resolution tandem mass spectrometry — developed within the broader GHS-R1a-agonist analytical literature, including work on the related compound anamorelin ^[16] — give anti-doping laboratories detection windows extending from hours to days post-administration.

Outside the regulatory domain, a 2025 scoping review in the Journal of Cachexia, Sarcopenia and Muscle examined the role of peptides in skeletal muscle wasting across 126 studies and identified 87 distinct peptides associated with muscle-mass, strength, or performance outcomes ^[11]. Ghrelin and ghrelin-receptor agonists — the class to which ipamorelin belongs — ranked among the most-studied. The review situates ipamorelin within an active translational pipeline for cachexia and sarcopenia research, but does not report new human efficacy data specific to ipamorelin. The most recent comprehensive ipamorelin clinical record remains the Beck 2014 trial ^[7].

Ipamorelin binds GHS-R1a — a Gq/11-coupled G-protein-coupled receptor expressed on anterior-pituitary somatotrophs and several other tissues — and activates phospholipase C, generating inositol trisphosphate and diacylglycerol ^[10]. Inositol trisphosphate releases calcium from intracellular stores and triggers L-type voltage-gated calcium influx; the resulting rise in cytosolic calcium drives growth hormone exocytosis from somatotroph vesicles. The pathway is mechanistically distinct from the cyclic-AMP-mediated growth hormone-releasing hormone receptor pathway, which is why combined administration of a GHRH analog and a GHRP can produce supra-additive growth hormone pulses in pulsatile-versus-tonic research models ^[10][17]. GHS-R1a also exhibits high constitutive (ligand-independent) activity in somatotroph cells, contributing to basal growth hormone pulsatility and modulating the magnitude of ipamorelin-evoked responses ^[9].